You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
INDICATIONS AS AT 21 JUNE 2005 : DIFLUCAN, given orally, is indicated for: 1. Treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin B. NOTE : Data suggest that the clinical efficacy of DIFLUCAN is lower than that of amphotericin B in the treatment of the acute phase of cryptococcal meningitis. 2. Maintenance therapy to prevent relapse of cryptococcal meningitis in patients with AIDS. 3. Treatment of oropharyngeal and oesophageal candidiasis in AIDS and other immunosuppressed patients. 4. Secondary prophylaxis of oropharyngeal candidiasis in patients with HIV infection. 5. Serious and life-threatening candida infections in patients who are unable to tolerate amphotericin B. NOTE : It remains to be shown that DIFLUCAN is as effective as amphotericin B in the treatment of serious and life-threatening Candida infections. Until such data are available, amphotericin B remains the drug of choice. 6. Vaginal candidiasis when topical therapy has failed. 7. Treatment of extensive tinea corporis, extensive tinea cruris and extensive tinea pedis infections in immunocompetent patients in whom topical therapy is not a practical treatment option. Usually, topical therapy should be attempted first because oral therapy has a less favourable ratio of benefits to risks (see ADVERSE REACTIONS). DIFLUCAN IV is indicated for the same conditions in adults and children but should be used only when DIFLUCAN cannot be administered orally.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
INDICATIONS AS AT 21 MAY 2004 : DIFLUCAN, given orally, is indicated for: 1. Treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin B. NOTE : Data suggest that the clinical efficacy of DIFLUCAN is lower than that of amphotericin B in the treatment of the acute phase of cryptococcal meningitis. 2. Maintenance therapy to prevent relapse of cryptococcal meningitis in patients with AIDS. 3. Treatment of oropharyngeal and oesophageal candidiasis in AIDS and other immunosuppressed patients. 4. Secondary prophylaxis of oropharyngeal candidiasis in patients with HIV infection. 5. Serious and life-threatening candida infections in patients who are unable to tolerate amphotericin B. NOTE : It remains to be shown that DIFLUCAN is as effective as amphotericin B in the treatment of serious and life-threatening Candida infections. Until such data are available, amphotericin B remains the drug of choice. 6. Vaginal candidiasis when topical therapy has failed. 7. Treatment of extensive tinea corporis, extensive tinea cruris and extensive tinea pedis infections in immunocompetent patients in whom topical therapy is not a practical treatment option. Usually, topical therapy should be attempted first because oral therapy has a less favourable ratio of benefits to risks (see ADVERSE REACTIONS). DIFLUCAN IV is indicated for the same conditions in adults and children but should be used only when DIFLUCAN cannot be administered orally.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on November, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
INDICATIONS AS AT 21 JUNE 2005 : DIFLUCAN, given orally, is indicated for: 1. Treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin B. NOTE : Data suggest that the clinical efficacy of DIFLUCAN is lower than that of amphotericin B in the treatment of the acute phase of cryptococcal meningitis. 2. Maintenance therapy to prevent relapse of cryptococcal meningitis in patients with AIDS. 3. Treatment of oropharyngeal and oesophageal candidiasis in AIDS and other immunosuppressed patients. 4. Secondary prophylaxis of oropharyngeal candidiasis in patients with HIV infection. 5. Serious and life-threatening candida infections in patients who are unable to tolerate amphotericin B. NOTE : It remains to be shown that DIFLUCAN is as effective as amphotericin B in the treatment of serious and life-threatening Candida infections. Until such data are available, amphotericin B remains the drug of choice. 6. Vaginal candidiasis when topical therapy has failed. 7. Treatment of extensive tinea corporis, extensive tinea cruris and extensive tinea pedis infections in immunocompetent patients in whom topical therapy is not a practical treatment option. Usually, topical therapy should be attempted first because oral therapy has a less favourable ratio of benefits to risks (see ADVERSE REACTIONS). DIFLUCAN IV is indicated for the same conditions in adults and children but should be used only when DIFLUCAN cannot be administered orally.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on November, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
INDICATIONS AS AT 21 JUNE 2005 : DIFLUCAN, given orally, is indicated for: 1. Treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin B. NOTE : Data suggest that the clinical efficacy of DIFLUCAN is lower than that of amphotericin B in the treatment of the acute phase of cryptococcal meningitis. 2. Maintenance therapy to prevent relapse of cryptococcal meningitis in patients with AIDS. 3. Treatment of oropharyngeal and oesophageal candidiasis in AIDS and other immunosuppressed patients. 4. Secondary prophylaxis of oropharyngeal candidiasis in patients with HIV infection. 5. Serious and life-threatening candida infections in patients who are unable to tolerate amphotericin B. NOTE : It remains to be shown that DIFLUCAN is as effective as amphotericin B in the treatment of serious and life-threatening Candida infections. Until such data are available, amphotericin B remains the drug of choice. 6. Vaginal candidiasis when topical therapy has failed. 7. Treatment of extensive tinea corporis, extensive tinea cruris and extensive tinea pedis infections in immunocompetent patients in whom topical therapy is not a practical treatment option. Usually, topical therapy should be attempted first because oral therapy has a less favourable ratio of benefits to risks (see ADVERSE REACTIONS). DIFLUCAN IV is indicated for the same conditions in adults and children but should be used only when DIFLUCAN cannot be administered orally.
Standard blue opaque cap with a white, opaque body; No.2 size capsules; overprinted with the Pfizer Logo & the code FLU-100 (Batch11292033 "DIFLUCAN 100").
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on November, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
INDICATIONS AS AT 21 MAY 2004 : DIFLUCAN, given orally, is indicated for: 1. Treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin B. NOTE : Data suggest that the clinical efficacy of DIFLUCAN is lower than that of amphotericin B in the treatment of the acute phase of cryptococcal meningitis. 2. Maintenance therapy to prevent relapse of cryptococcal meningitis in patients with AIDS. 3. Treatment of oropharyngeal and oesophageal candidiasis in AIDS and other immunosuppressed patients. 4. Secondary prophylaxis of oropharyngeal candidiasis in patients with HIV infection. 5. Serious and life-threatening candida infections in patients who are unable to tolerate amphotericin B. NOTE : It remains to be shown that DIFLUCAN is as effective as amphotericin B in the treatment of serious and life-threatening Candida infections. Until such data are available, amphotericin B remains the drug of choice. 6. Vaginal candidiasis when topical therapy has failed. 7. Treatment of extensive tinea corporis, extensive tinea cruris and extensive tinea pedis infections in immunocompetent patients in whom topical therapy is not a practical treatment option. Usually, topical therapy should be attempted first because oral therapy has a less favourable ratio of benefits to risks (see ADVERSE REACTIONS). DIFLUCAN IV is indicated for the same conditions in adults and children but should be used only when DIFLUCAN cannot be administered orally.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on November, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
INDICATIONS AS AT 21 MAY 2004 : DIFLUCAN, given orally, is indicated for: 1. Treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin B. NOTE : Data suggest that the clinical efficacy of DIFLUCAN is lower than that of amphotericin B in the treatment of the acute phase of cryptococcal meningitis. 2. Maintenance therapy to prevent relapse of cryptococcal meningitis in patients with AIDS. 3. Treatment of oropharyngeal and oesophageal candidiasis in AIDS and other immunosuppressed patients. 4. Secondary prophylaxis of oropharyngeal candidiasis in patients with HIV infection. 5. Serious and life-threatening candida infections in patients who are unable to tolerate amphotericin B. NOTE : It remains to be shown that DIFLUCAN is as effective as amphotericin B in the treatment of serious and life-threatening Candida infections. Until such data are available, amphotericin B remains the drug of choice. 6. Vaginal candidiasis when topical therapy has failed. 7. Treatment of extensive tinea corporis, extensive tinea cruris and extensive tinea pedis infections in immunocompetent patients in whom topical therapy is not a practical treatment option. Usually, topical therapy should be attempted first because oral therapy has a less favourable ratio of benefits to risks (see ADVERSE REACTIONS). DIFLUCAN IV is indicated for the same conditions in adults and children but should be used only when DIFLUCAN cannot be administered orally.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
INDICATIONS AS AT 21 MAY 2004 : DIFLUCAN, given orally, is indicated for: 1. Treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin B. NOTE : Data suggest that the clinical efficacy of DIFLUCAN is lower than that of amphotericin B in the treatment of the acute phase of cryptococcal meningitis. 2. Maintenance therapy to prevent relapse of cryptococcal meningitis in patients with AIDS. 3. Treatment of oropharyngeal and oesophageal candidiasis in AIDS and other immunosuppressed patients. 4. Secondary prophylaxis of oropharyngeal candidiasis in patients with HIV infection. 5. Serious and life-threatening candida infections in patients who are unable to tolerate amphotericin B. NOTE : It remains to be shown that DIFLUCAN is as effective as amphotericin B in the treatment of serious and life-threatening Candida infections. Until such data are available, amphotericin B remains the drug of choice. 6. Vaginal candidiasis when topical therapy has failed. 7. Treatment of extensive tinea corporis, extensive tinea cruris and extensive tinea pedis infections in immunocompetent patients in whom topical therapy is not a practical treatment option. Usually, topical therapy should be attempted first because oral therapy has a less favourable ratio of benefits to risks (see ADVERSE REACTIONS). DIFLUCAN IV is indicated for the same conditions in adults and children but should be used only when DIFLUCAN cannot be administered orally.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
